Evidence map›Paper›PMID 31004579›Full record

ArticleJournal of immunological methods2019

Development of a novel multiplex electrochemiluminescent-based immunoassay to aid enterotoxigenic Escherichia coli vaccine development and evaluations.

Subhra Chakraborty, Jessica Brubaker, Clayton Harro, Thomas Weirzba, David Sack

Open access · hybridAbstract read
In one paragraph

Article in Journal of immunological methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Cells · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Subhra ChakrabortyDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: schakr11@jhu.edu.
Jessica BrubakerDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Clayton HarroDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Thomas WeirzbaPATH, Washington, DC, USA.
David SackDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Johns Hopkins University · USProgram for Appropriate Technology in Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enterotoxigenic Escherichia coli (ETEC) is a leading cause of bacterial diarrhea both among children in low and middle income countries and in travelers to these regions. Although there are several approaches to develop an effective vaccine for ETEC, no licensed vaccines are currently available. The most advanced ETEC vaccine candidates include multiple colonization factors along with the heat labile toxin B subunit. In the absence of known correlates of protection, and to understand the mechanism of protection, monitoring immune responses to a majority of the vaccine associated antigens using various types of samples is needed. Unfortunately, a traditional ELISA is time consuming, labor intensive and requires substantial amounts of antigens and sample volumes. To address these constraints, we developed and validated a novel high throughput electrochemiluminescent (ECL) - based multiplex immunoassay using Meso Scale Discovery (MSD) platform for analyzing immune responses to ETEC antigens. The ETEC multiplex ECL assay is an 8-plex assay which includes the ETEC colonization factor antigens (CFA/I, CS1, CS2, CS3, CS5 and CS6) along with the two subunits of heat labile toxin (LTA and LTB). Our data suggested that a single dilution of sample provides a quantifiable result for a wide range of sample titers. To compare ETEC multiplex ECL with ELISA, we carried out assays using the same antigens with the two immunoassay platforms using a common sample set of serum and ALS (antibodies in lymphocyte supernatant) specimens. The MSD platform achieved excellent correlations with ELISA for the antigens tested, consistently detecting comparable antibody levels in the samples. The ETEC multiplex ECL can serve as a fundamental platform in evaluating performances of candidate ETEC vaccines in future field trials.

Indexed as

Antibodies, BacterialAntigens, BacterialBacterial ToxinsElectrochemical TechniquesEnterotoxigenic Escherichia coliEscherichia coli InfectionsEscherichia coli ProteinsEscherichia coli VaccinesHumansImmune SeraImmunoassayLuminescenceLuminescent MeasurementsReproducibility of ResultsSensitivity and SpecificityAntibodies, BacterialAntigens, BacterialBacterial ToxinsEscherichia coli ProteinsEscherichia coli VaccinesImmune SeraELISAETECImmune responsesMultiplex ECLVaccine

Identifiers

PMID31004579
PMCPMC6538825
OpenAlexW2940234690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.